Phase I/ IB Multicenter Open-Label Study of RMC-6236 in Patients with Advanced Solid Tumors Harboring Specific Mutations in KRAS
Summary
The purpose of this study is to evaluate the safety and feasibility of RMC- 6236 in adults with KRAS mutant advanced solid tumors, including pancreatic cancer.
General Information
NCT#: NCT05379985
Study ID: RMC-6236-001
Trial Phase: Phase I
Trial Sponsor: Revolution Medicines, Inc.
Therapies Used in This Trial: RMC- 6236